CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
MEDI-575drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01268566
NCT01268566Phase 2Completed
CompareCT.gov

A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme

MedImmune LLC·interventional·Posted Dec 31, 2010·Updated Apr 6, 2017

In Brief

A Phase 2 clinical trial evaluating MEDI-575 for Glioblastoma Multiforme. Completed, enrolled 62 participants across 12 sites.

Detailed Summary

The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 31, 2010
Enrollment StartJan 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.5 years ago

Interventions

MEDI-575drug

MEDI-575 as an IV infusion.